JournalㄩIn Vitro Cellular & Developmental Biology - Animal
AuthorsㄩChen Yang, Xiaojuan Liu, Fangfang Yang, Weixun Zhang, Zihao Chen, Daliang Yan, Qingsheng You, Xiang Wu
Published dateㄩ2017-03 (Published online: 2016-11-04)
Volumeㄩ53
Issueㄩ3
Pagesㄩ248每257
DOIㄩ10.1007/s11626-016-0105-2
PMIDㄩ27815660
PDF linkㄩhttps://link.springer.com/content/pdf/10.1007/s11626-016-0105-2.pdf
Article linkㄩhttps://doi.org/10.1007/s11626-016-0105-2
PubMed linkㄩhttps://pubmed.ncbi.nlm.nih.gov/27815660/
Article SourceㄩSpringer Nature / PubMed
Article TitleㄩMitochondrial phosphatase PGAM5 regulates Keap1-mediated Bcl-xL degradation and controls cardiomyocyte apoptosis driven by myocardial ischemia/reperfusion injury
Contentㄩ
1. Research Background
Myocardial ischemia/reperfusion (I/R) injury occurs when blood supply to the heart is interrupted and subsequently restored. Although reperfusion is essential to save the heart muscle, it can also trigger additional cellular damage and cardiomyocyte apoptosis.
PGAM5 is a mitochondrial phosphatase involved in cellular stress responses. Keap1 is a regulatory protein involved in protein degradation and cellular stress signalling, while Bcl-xL is an anti-apoptotic protein that helps cells survive by inhibiting programmed cell death.
2. Research Objective
The study investigated how mitochondrial PGAM5 regulates Keap1-mediated degradation of Bcl-xL and whether this pathway contributes to cardiomyocyte apoptosis following myocardial ischemia/reperfusion injury.
3. Proposed Molecular Mechanism
The research examined the relationship between PGAM5, Keap1, and Bcl-xL in the regulation of cardiomyocyte survival.
Simplified pathway:
Myocardial ischemia/reperfusion injury ↙ PGAM5-associated signalling ↙ Keap1-mediated Bcl-xL degradation ↙ reduced anti-apoptotic protection ↙ increased cardiomyocyte apoptosis.
This pathway provides a framework for understanding how mitochondrial stress signalling may influence heart-cell survival.
4. Research Significance
The study links mitochondrial signalling with the regulation of an anti-apoptotic protein during myocardial injury. Understanding this mechanism may help researchers identify molecular targets for reducing cardiomyocyte loss during ischemia/reperfusion.
5. Conclusion
The article investigates PGAM5 as a regulator of Keap1-mediated Bcl-xL degradation and cardiomyocyte apoptosis associated with myocardial ischemia/reperfusion injury. The findings provide mechanistic evidence for further investigation of PGAM5-related pathways in cardiac protection.
6. Relevance to the AI-Driven Drug Discovery for Acute Myocardial Infarction Project
This paper is relevant to the literature review and molecular-target identification stages of the project.
Potential applications include:
- Investigating PGAM5 as a candidate molecular target.
- Analysing the Keap1每Bcl-xL pathway and its relationship to cardiomyocyte survival.
- Identifying compounds that may modulate the pathway.
- Comparing this apoptosis-related mechanism with PGAM5每Drp1-associated mitochondrial dysfunction and necroptosis.
- Assessing whether candidate interventions could reduce cardiac damage during reperfusion.
7. Limitations and Evidence Status
This paper is mechanistic research, not evidence of an approved treatment. Its findings should not be interpreted as proof that PGAM5 inhibition is safe or effective in human heart-attack patients. The experimental models, methods, effect sizes, and detailed results should be reviewed from the full article before drawing conclusions about therapeutic potential.
Remarkㄩ
Relevant research for understanding mitochondrial stress signalling and cardiomyocyte apoptosis during myocardial ischemia/reperfusion injury. This article can support target discovery and mechanistic analysis in the AI-driven drug discovery project. PGAM5 and the Keap1每Bcl-xL pathway should be treated as research candidates requiring further validation, not established clinical treatment targets.
|
20
Finite Element-Based Structural Optimization for UAV Storage-Launch Container
